STUDY QUESTION: Are there any differences in the molecular characteristics of the luteal granulosa cells (GC) obtained from stimulated versus non-stimulated (natural) IVF cycles that may help explain the defective luteal phase in the former?
Introduction
The natural ovarian cycle in human is characterized by the recruitment, development and ovulation of a single follicle (mono-ovulatory) and hence, the presence of a single corpus luteum. By contrast, in IVF cycles, controlled ovarian stimulation (COS) initiated at early follicular phase with exogenously administered gonadotrophin hormones overrides the natural selection process of a single dominant follicle and produces multiple ovulatory follicles. As a result, these cycles are also characterized by the presence of multiple corpora luteae after ovulation is triggered either conventionally with hCG or with a GnRH agonist. The GnRH agonist trigger is exclusively used when there is a risk of ovarian hyperstimulation syndrome (OHSS) in which the ovaries hyper-respond to gonadotrophin stimulation by producing too many growing follicles along with development of ascites, pleural effusion and hemo-concentrations as a result of increased vascular permeability and leakage of intravascular volume into third spaces (Humaidan et al., 2010 Mascarenhas and Balen, 2017) . The GnRH agonist ovulation trigger strategy is also used when early luteolysis and rapid reduction in serum estrogen level are indicated such as random-start ovarian stimulation protocols employed for oocyte and embryo freezing in patients with estrogen sensitive tumors, for example breast cancer (Oktay et al., 2010) . It is well documented that the function of corpus luteum is defective in stimulated IVF cycles (Fatemi, 2009 ). This necessitates progesterone (P 4 ) and/ or hCG administration, known as luteal phase support, in order to improve clinical pregnancy rates and prevent miscarriage (Pritts and Atwood, 2002; van der Linden et al., 2011) . Luteal phase becomes shorter and menstruation begins earlier than a natural cycle if pregnancy could not be achieved, indicative of the early demise of corpus luteum (premature luteolysis). If conception occurs, the pregnancy rate declines without luteal phase support, suggesting that existing corpora lutea do not sufficiently support the maintenance of pregnancy (Pritts and Atwood, 2002) . Those IVF cycles in which ovulation is triggered with a GnRH agonist without coadministration of hCG appear to have the most defective luteal phase such that clinical pregnancy rate is drastically reduced even with exogenous progesterone supplementation if a fresh embryo transfer in that cycle is performed . It is unclear why luteal function is defective and requires exogenous support in stimulated IVF cycles. According to our current understanding, supra-physiological levels of steroids produced by multiple corpora lutea during COS cause a luteal phase defect by directly inhibiting LH release via negative feedback actions on the hypothalamic-pituitary-ovarian axis (HPO) (Fauser and Devroey, 2003; Fatemi, 2009) . We hypothesized that differences may exist between natural and stimulated IVF cycles in terms of the ability of GC to survive and maintain their viability and steroidogenic activity that potentially may help to explain, at least in part, defective luteal function in stimulated cycles. To the best of our knowledge, this issue has not been studied at a molecular level in human before.
Materials and Methods
This study was approved by the institutional review board of Koc University (IRB# 2017.141.IRB2.049) . Informed written consents were obtained from all participants.
Patients
All expected normo-responders and predicted high-responders without polycystic ovary syndrome (PCOS) were included in this study. We did not include predicted or documented poor responders (defined according to the Bologna criteria; Ferraretti et al., 2011) and high-responders with PCOS because patients in these categories might have distinct underlying molecular aberrations that may confound the results. All eligible IVF patients were invited to participate in this study over a 6-month period between September 2017 and April 2018. Since the minimum number of patient samples required for the experiments were determined after power analysis calculations, active enrollment of the patients was continued until the required sample numbers were reached. A total of 154 IVF patients who consented to allow their GC to be used for research were finally included in the study. The high-responders had high-ovarian reserve but were not diagnosed with PCOS based on ovarian morphology, clinical and laboratory parameters.
The natural cycle IVF group consisted of 22 patients who presented for oocyte freezing at pre-ovulatory phase and therefore underwent oocyte retrieval after ovulation was induced with recombinant hCG (rhCG). The indications for oocyte freezing were elective (n = 18) and fertility preservation prior to cancer therapy (n = 4). The remaining 132 patients underwent COS with recombinant FSH using the GnRH agonist long protocol (n = 44) and antagonist protocol triggered with rhCG (n = 46) or GnRH agonist leuprolide acetate (Abbott Pharmaceutical Products, USA) (n = 42). While hCG-triggered GnRH agonist and antagonist protocols were mainly used for the patients who were predicted to have normal response to ovarian stimulation (4-15 oocytes), the agonist-triggered antagonist protocol was mainly used for the predicted high responders (≥16 oocytes) (Drakopoulos et al., 2016) .
Isolation and culture of human luteinized GC from follicular fluid Follicular fluids were obtained from IVF patients during the oocyte retrieval procedure and luteinized GC were isolated from this fluid as we described previously (Bildik et al., 2015) . Oocyte retrieval was performed 36 h after ovulation trigger. Recovered luteal GC were processed and analyzed separately for each individual patient. The follicular aspirates from each patient were pooled in conical bottomed 50-ml centrifuge tubes and centrifuged at 500 × g for 5 min at room temperature. At this speed, the resulting pellet shows no layering. The supernatant was aspirated using a Pasteur pipette connected to a vacuum line. To remove erythrocyte contamination, the hypo-osmotic lysis technique was performed as described previously (Lobb and Younglai, 2006) . Sterile distilled water (9 ml) was added to the cell slurry remaining in the bottom of the tube after supernatant aspiration, and the tube was capped and mixed. After 30 s, 1 ml of 10× concentrated PBS, pH 7.4, was added and the tube was capped and mixed. The tubes were then centrifuged at 500 × g for 5 min at room temperature. The cell pellet was re-suspended in 0.5 ml of culture media and counted for cell number and viability in 0.2% trypan blue on a hemocytometer. The recovered cells were either cultured or processed for other experiments. For culture, the cells were seeded in six-well format culture plates at a density of 25 000-50 000 cells per well using DMEM-F12 culture medium supplemented with 10% fetal bovine serum at 37°C and 5% CO 2 .
Viability assay
A live/dead cell assay was performed with YO-PRO-1 (1 mM), a green fluorescent carbocyanine nucleic acid stain absorbed by only apoptotic cells, whereas live cells are impermeable to it. Hoechst 33342 (1 μg/ml) was used for counterstaining. Live/dead cell imaging of the cells was undertaken under appropriate channels using a fluorescence microscope (IX71; Olympus ,Tokyo, Japan).
Gene expression analysis
RNA isolation from GC was performed with Quick-RNA MicroPrep Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions. RNA was quantified with a spectrophotometric read at 260 nm using Nanodrop 2000 (Thermo Fisher Scientific, MA, USA) and 500 ng cDNA was prepared by using the M-MLV Reverse Transcriptase (Invitrogen, CA, USA). The mean co-efficient of variation in RNA yields of the samples was 7.2%, which appeared to have a small effect on the reliability of the results. The expression of mRNAs of interest was compared using quantitative real-time RT-PCR (qRT-PCR) and Light Cycler 480 SYBR Green I Master (Roche, Germany). The PCR primers for the genes investigated in the study [steroidogenic enzymes, LH receptor, pro-apoptotic/anti-apoptotic genes, vascular endothelial growth factor (VEGF)] are shown in Table I . RT-PCR experiments were repeated four times. For each experiment, 3 different readouts were obtained for each gene of interest.
Hormone assays
Estradiol (E 2 ) and P 4 levels in culture media were determined using an electrochemiluminescence immunoassay (ECLIA) (Elecsys and Cobas immunoassay analyzers; Roche Diagnostics, Germany). Lower detection limits for E 2 and P 4 were 5.00 pg/ml (18.4 pmol/ml) and 0.030 ng/ml (0.095 nmol/ml), respectively.
Immunoblotting
The 3β-hydroxysteroid dehydrogenase (3β-HSD) Type II (sc-100466), steroidogenic acute regulatory protein (StAR) (sc-166821) and cholesterol side-chain cleavage enzyme (p450SCC) (CYP11 A1, sc-292456) monoclonal antibodies were purchased from Santa Cruz Biotechnology, Inc. (TX, USA). Mouse monoclonal antibody against human progesterone (LS-C194163) was purchased from LifeSpan BioSciences (Seattle, WA, USA). Aromatase (CYP19A, ab34193) monoclonal mouse antibody was from Abcam (Abcam Inc., MA, USA). Anti-vinculin antibody (Sigma-Aldrich, St. Louis, MO, USA) was used as loading control at a dilution of 1:10 000. Cell lysates for western blot were prepared using radioimmunoprecipitation assay buffer (Sigma-Aldrich) as we described previously (Oktem et al., 2017) . Immun-Blot ® PVDF Membranes (BioRad, CA, USA) were incubated overnight at 4°C with the antibodies at the concentrations recommended by the manufacturers.
Statistical analysis
Samples size required for statistical significance and proper interpretation of the results were calculated based on the qRT-PCR assays. We have used the ΔΔCt method for relative quantitation of target gene mRNAs (Livak and Schmittgen, 2001; Oktem et al., 2017) . The mean and SD were calculated from 3 different readouts taken for each target gene in the RT-PCR assay. As an example, the mean and SD of the target gene stAR were calculated after 3 different readouts taken for each individual sample of 22 natural cycle IVF patients, giving a total 66 (22 × 3) readouts with SD ranging from 0.05 to 0.1. Similar SDs were obtained in the readouts of other target genes. Therefore, the experiment will have a 80% power to detect a difference between the means of 0.09 with a significance level of 0.05 if we had at least 20 samples. mRNA levels of the target genes used in the qRT-PCR assay (steroidogenic enzymes, LH receptor, pro-apoptotic/antiapoptotic genes, VEGF) and hormone levels are continuous variables therefore, expressed as the mean ± SD. ANOVA/ Bonferroni or KruskalWallis/Dunn's post hoc tests were applied to compare the groups if data are parametric or non-parametric respectively. The percentages of viable and apoptotic cells were compared between the groups using Fisher's exact test. Significance level was set at 5% (P < 0.05), and the SPSS statistical program (version 22) (IBM Software, NY, USA) was used to analyze the data.
Results
Demographic and IVF cycle characteristics of the patients are summarized in Table II . Natural and stimulated IVF cycles were comparable in terms of age, gonadotrophin dose and duration of stimulation. However, the peak E 2 levels on the hCG day and the number of oocytes retrieved were significantly higher in the agonist-triggered antagonist cycles compared to the others. Serum P 4 level on the hCG day was significantly lower in the natural cycles in comparison to the other types of stimulated cycles.
Viability assay
First, we carried out a simple viability assay with green fluorescent carbocyanine uptake in the luteal GC immediately after they were recovered from follicular aspirates during oocyte retrieval procedure. We found that natural cycle GC were significantly more viable (88% viable cells) compared to their counterparts of the stimulated IVF cycles (66, 64 and 37% for agonist and antagonist cycles triggered with hCG and GnRH agonist, respectively, P < 0.01, Fig. 1A and B).
Comparison of the expression of steroidogenic enzymes and in vitro E 2 and P 4 production of the luteal GC
The expression of ovarian steroidogenic enzymes stAR, SCC, 3β-HSD and aromatase was significantly higher in GC from the agonist and hCG-triggered antagonist cycles compared to natural cycle in both RT-PCR and quantitative immunoblotting analyses (Fig 2A-C) . 3β-HSD, VEGF and LH mRNA expressions in the cells obtained from agonist-triggered antagonist cycles were significantly lower than natural, agonist and hCG-triggered antagonist cycles (Fig 2A-C) . In line with this finding, when plated at equal density, in vitro E 2 and P 4 production in the cells from the stimulated cycles was significantly higher than in those of natural cycles in the first days of culture. However, on the following days the hormone production in cells from the stimulated cycles began to decline gradually. By contrast, such a decline was not observed in the natural cycle GC, which continued to produce E 2 and P 4 hormones in increasing amounts during the same culture period. The most defective steroid output was observed in the agonisttriggered antagonist cycles, with E 2 and P 4 production drastically reducing during the 6-day culture period (Fig 3A and B) . We also investigated if patient age and serum P 4 level on the hCG day have any impact on the expression of steroidogenic enzymes and viability of the cells. There was an inverse correlation between patient age and the number of oocytes retrieved. However, neither patient age nor serum P 4 level on the day of hCG trigger were associated with the level of expression of steroidogenic enzymes and viability of the cells (Supplementary Figs S1 and S2 ).
hCG treatment up-regulates the expression of steroidogenic enzymes, LH receptor and anti-apoptotic genes and improves survival and P production of the luteal GC We hypothesized that declining in vitro E 2 and P 4 productions in the luteal GC from the stimulated IVF cycles, and particularly in the agonist-triggered cycles, might be due to increased cell death. To test our hypothesis, we monitored viability of the cells for 6 days in culture and observed that natural cycle GC maintained their vitality in culture compared to their counterparts from the stimulated IVF cycles: at the end of 6-day culture period, 74% of the natural cycle GC were still viable whereas only 48, 43 and 22% of the cells from the agonist and antagonist cycles triggered with hCG and agonist respectively, were viable (P < 0.01). Next, we compared the mRNA expression of the genes involved in cell survival/apoptosis and found out that antiapoptotic Akt-1 and BCL-L2 were significantly down-regulated and pro-apoptotic BAD, BAX and Casp3 were significantly elevated in the cells from the stimulated IVF cycles especially in the agonist-triggered antagonist cycles in comparison to natural cycle granulosa cells (GC) (Fig. 4) .
So far, our findings indicate that reduced viability and defective mRNA expression levels of LH receptor and the anti-apoptosis gene BCL-L2 in the cells from the agonist and hCG-triggered antagonist cycles as well as additional defective mRNA expression of 3β-HSD and VEGF in the agonist-triggered antagonist cycles may account for compromised luteal function in the stimulated IVF cycles. Therefore, in another set of experiments we treated GC from the agonist-triggered cycles with rhCG for 24 h and observed that hCG treatment significantly improved the viability, up-regulated the mRNA expression of 3β-HSD, LH receptor, VEGF and BCL-L2, and increased P 4 output from the cells compared to their counterparts not incubated with hCG (Fig. 5) .
Discussion
We have shown in this study that there are several differences in the molecular characteristics of luteal GC obtained from natural versus stimulated IVF cycles that might be related to defective luteal function in the latter. First, luteal GC obtained from natural cycles are more viable ex vivo and more capable of maintaining their vitality and steroidogenic activity in vitro in comparison to the stimulated IVF cycles. Second, natural cycle GC express LH receptor and anti-apoptotic genes at higher levels compared to their counterparts obtained from stimulated IVF cycles. Third, the mRNA expression of LH receptor, VEGF and 3β-HSD, the enzyme responsible for conversion of pregnenolone to progesterone, are most defective in the luteal GC from the agonisttriggered antagonist cycles, leading to more severely compromised luteal function. hCG administration appears to reverse these defects and improves cell viability and P 4 output from these cells.
It is not clearly understood why luteal function is defective and requires exogenous support in the stimulated IVF cycles despite the presence of multiple corpora lutea. Several theories have been proposed to explain this phenomenon. It was initially thought that traumatic injury of corpora lutea and removal of some portions of luteinized mural GC during oocyte retrieval procedure cause defects in luteal steroid production. But this theory was later refuted because it was demonstrated that aspiration of a single follicle did not cause any luteal defect in women with normal ovulatory cycles (Kerin et al., 1981) . Another theory holds that GnRH agonist and antagonists used to prevent a premature LH surge may cause a prolonged pituitary recovery resulting in low LH levels and defects in corpus luteum in the stimulated cycles (Smitz et al., 1992; Pritts and Atwood, 2002) . Lack of LH was thought to be caused by hCG administration, however it was shown later that hCG administration does not reduce LH secretion in the natural cycle of normal ovulatory women (Tavaniotou and Devroey, 2003) . Our current understanding suggest that supra-physiological levels of steroids produced by multiple corpora lutea directly inhibit LH release via negative feedback actions on the HPO axis (Fauser and Devroey, 2003; Fatemi, 2009) . Human and primate studies documented that a constant LH stimulus is required for maintenance and steroidogenic activity of the corpus luteum (Jones, 1991) . Therefore, the length of luteal phase is shortened due to premature luteolysis occurring secondary to low-levels of endogenous LH in stimulated IVF cycles. As another possibility, this phenomenon might also be related to ovarian physiology in human itself, which is characterized by mono-follicular development and the formation of a single corpus luteum. COS overrides the process of dominant follicle selection and produces multiple ovulatory follicles. If dominant follicle selection from a cohort of antral follicles is not a random event and there is a quality check, COS bypasses this process and allows the growth of other antral follicles, which would otherwise undergo atresia in a natural cycle. Resultant multi-follicular development may exceed the ability of ovary to produce multiple corpora lutea with adequate luteal function. The question of why the most defective luteal function is observed in the antagonist cycles triggered with a GnRH agonist might be explained by the fact that the short half-life of the endogenous LH surge induced by the flare effect of exogenously administered GnRH agonist might not be sufficient to induce adequate expression of 3β-HSD, LH receptor and VEGF, which appeared to be defective in these cycles. Furthermore, LH and hCG action on the same receptor does not necessarily result in activation of the same signaling pathways as there appear to be some quantitative and qualitative differences in intracellular signaling after hCG and LH stimulation of LH receptors. Also the highest serum E 2 levels are attained in the high-responders in whom ovulation is triggered with a GnRH agonist. It is therefore not surprising to anticipate the strongest negative feedback inhibition of the HPO axis and hence the lowest LH levels and most defective luteal Figure 1 Live/dead cell assay with YO-PRO-1 green fluorescent carbocyanine uptake. Viability of the luteal granulosa cells (GC) immediately after they were recovered from follicular aspirates during oocyte retrieval procedure were analyzed by YO-PRO-1 uptake. Natural cycle GC were significantly more viable (88%) compared to their counterparts of the stimulated IVF cycles (66, 64 and 37% for agonist and antagonist cycles triggered with hCG and GnRH agonist respectively, scale bar: 50 μm).
function in this group of IVF patients. Up-regulated expression of LH receptor, 3β-HSD and VEGF, plus enhanced viability and increased P 4 output after hCG "rescue" treatment of the cells obtained from these cycles not only provides a biological basis for the co-administration of hCG with a GnRH agonist to induce ovulation but also confirms one more time its critical role as a luteal phase support. Figure 2 Comparison of the mRNA and protein expression of the steroidogenic enzymes in the luteal GC from natural versus stimulated IVF cycles. The expression of ovarian steroidogenic enzymes steroidogenic acute regulatory protein (stAR), cholesterol side-chain cleavage enzyme (SCC), 3β-Hydroxysteroid dehydrogenase (3β-HSD) and aromatase was significantly higher in the GC from the agonist and hCG-triggered antagonist cycles compared to natural cycle in both quantitative RT-PCR (qRT-PCR) (A) and quantitative immunoblotting analyses (B and C). However, 3β-HSD, vascular endothelial growth factor (VEGF) and LH expression was significantly lower in the cells from agonist-triggered antagonist cycles than natural, agonist and hCG-triggered antagonist cycles. Figure 3 Comparison of in vitro estradiol and progesterone production of the luteal GC from natural versus stimulated IVF cycles. In vitro estradiol (E 2 ) and progesterone (P 4 ) production of the cells from the stimulated cycles were significantly higher than those of natural cycles in the first days of culture. However, on the following days their hormone production began to decline gradually. By contrast, such a decline was not observed in the natural cycle GC. They continued to produce E 2 and P 4 hormones in increasing amounts during the same culture period. The most defective steroid output was observed in the agonist-triggered antagonist cycles. Steroid production from the cells obtained from these cycles drastically reduced during 6-day culture period (A and B).
Previous studies showed that gene expression profiles of human GC might differ according the COS protocol as well as the mode of triggering for final oocyte maturation. Similar to our findings, Kaneko et al. (2000) observed that the incidence of GC apoptosis was lower in natural cycles compared to GnRH agonist stimulation cycles but somehow higher compared to hCG plus HMG stimulation cycles. Increased apoptosis of GC was initially linked to a reduction in oocyte quality, fertilization, pregnancy and live birth rate in several studies (Nakahara et al., 1997; Oosterhuis et al., 1998; Kaneko et al., 2000; Sifer et al., 2002) . However, it was later recognized that apoptosis of luteal GC is a crude marker and has a poor predictive capability regarding oocyte quality and IVF success (Regan et al., 2018) . With advancement of molecular techniques later studies were more focused on the molecular characterization of GC. Borgbo et al. (2013) reported significant differences in human mural (MGC) and cumulus granulosa cell (CC) transcriptomes when hCG or GnRH agonist were used for triggering ovulation. One hundred and fifty-seven genes displayed a lower expression, and 234 genes displayed a higher expression in GnRH agonist-triggered CC as compared with CC from hCG-triggered follicles. Seventy-eight genes displayed a lower expression, and 174 genes displayed a higher expression in GnRH agonist-triggered MGC as compared with MGC from hCG-triggered follicles. The mRNA expression of LH receptor, CYP11A1 and HSD3B1 were found at significantly higher levels in the CC of agonist-triggered antagonist cycles in comparison to hCG-triggered ones. The authors did not observe such an increase in the expression of these genes in the MGCs, of which upregulated expression was more significant for the genes involved in cell adhesion and extracellular matrix re-modeling. In both CC and MGC, LH was suggested as possible up-stream regulator. The up-stream regulator analysis predicted an activation of the LH and ERK regulatory cascade (extracellular signal regulated kinase of mitogen activated protein kinase family) in the CCs as differentially expressed genes, while no significant direction (activation or inhibition) prediction was present in the analysis of the MGC (Borgbo et al., 2013) . Later on, the same group reported that follicular fluid steroid levels and gene expression patterns did not differ according to the dose of GnRH agonist (triptorelin) used to trigger ovulation (Vuong et al., 2017) . Haas et al. (2016) compared hCG and dual trigger (hCG plus GnRH agonist) in terms of differential gene expression and showed that mRNA expression of amphiregulin and epiregulin (downstream regulators of epidermal growth factor signaling coupled to LH receptor activation during the ovulation process) were significantly higher in the dual trigger group compared with the hCG group.
Taken together, available data suggest that the mode of ovulation trigger is associated with an alteration in the gene expression profiles of CC and MGC. CC with their close proximity to, and extrusion with, the oocyte are more likely to be involved in the regulation of signaling pathways involved in oocyte maturation while the abundant MGC are a major source of progesterone production in corpus luteum (Russell et al., 2016) . Given that the LH surge during ovulation has two specific purposes, namely final oocyte maturation and transition from a follicular phenotype to a functioning corpus luteum, it is not surprising to observe the differences in the up and down-regulation of different genes post activation of LH receptor in these two different types of luteal GC, even after an ovulation trigger with the same hormone or agent. While there is sufficient evidence that GnRH agonist as a final oocyte maturation in fresh autologous cycles is not only associated with a lower risk of OHSS but also with lower live birth rates, lower ongoing pregnancy rates and high risk of miscarriages in the first trimester (Youssef et al., 2014) , it is unclear if triggering ovulation with a GnRH agonist alone or in combination with hCG improves mature oocyte yield, fertilization and pregnancy rates in comparison to hCGtriggered cycles (Humaidan et al., 2005; Oktay et al., 2010; Ding et al., 2017; Elias et al., 2017; Chen et al., 2018) . In our study, we did not find any significant difference between the antagonist cycles triggered with hCG versus agonist in terms of the numbers of total and mature oocytes retrieved.
Our study has several importation limitations. First, we simply showed that luteal GC obtained from the stimulated IVF cycles are less capable of maintaining their vitality and steroidogenic activity in vitro and have reduced LH receptor expression when compared to their counterparts from natural cycles as a possible explanation of defective luteal function in the former. We did not identify the underlying novel molecular pathogenetic mechanism(s) that links ovarian stimulation itself to the observed defects in luteal function in a cause and effect relationship. Second, the corpus luteum is a transient endocrine organ that is composed of different compartments and cell types (Duncan, 2000) . Its formation and regression (luteolysis) are characterized by a marked tissue re-modeling and vascular involution that involves many different cell types, signaling pathways, inflammatory mediators and the intriguing interactions between them. Therefore, luteinized GC are only one type of cell and might not reliably represent the actual in vivo mechanisms that regulate the survival and function of the whole corpus luteum. Third, the luteal phase of a typical menstrual cycle consists of different stages known as early, mid and late (Duncan, 2000) . Mural luteinized GC immediately recovered during an oocyte retrieval procedure belong to a very early stage of the luteal phase and information gathered during this phase might not be true for the rest of the phase. Fourth, ovulation was triggered with hCG in the natural cycles in our study in order to time oocyte retrieval accurately. Therefore, mural luteinized GC obtained from these cycles may not truly represent pure natural cycles in which ovulation is triggered naturally by the mid-cycle surge of endogenous LH. Fifth, since ovarian stimulation was achieved with recombinant FSH in our study, we do not know if LH supplementation would have any effect on the viability and the expression of steroidogenic enzymes, LH receptor and VEGF in the luteal GC. Sixth, there could be some differences inherent to the clinical characteristics of the patients undergoing natural versus stimulated IVF cycles that might have affected the results that we obtained. As a final limitation, it was not possible to correlate the stimulation-related molecular alterations in luteal GC with the clinical outcome since the oocytes retrieved in natural IVF cycles were all frozen and none have been utilized yet.
Conclusion
In this study we have provided the molecular evidence that COS itself and the mode of ovulation trigger are associated with significant alterations in the viability and steroidogenic activity of luteal GC. In addition to the negative feedback action of supra-physiological steroid levels on LH release in the HPO axis, the reduced cell viability, and suppressed expression of 3B-HSD, LH receptor and VEGF as well as an increased propensity to undergo apoptosis might all contribute to compromised steroid production in luteal GC and the luteal phase defects observed in the stimulated IVF cycles. It is unclear if a low-LH environment created during the course of COS is the only factor responsible for the observed defects in the luteal GC or some other mechanisms are also operative. As an additional finding, we have demonstrated that molecular characteristics of the luteal GC obtained from normal responding IVF patients undergoing ovarian stimulation with GnRH agonist long versus hCG-triggered antagonist protocols are similar in terms of viability and the expression of steroidogenic enzymes and LH receptor expression. A more thorough analysis of luteal function at the molecular level may help us to better understand the luteal phase and develop new strategies to improve it in assisted reproduction.
